AMBER Parts 1C and 1E: Phase I Trial of Cobolimab, an Anti–TIM-3 mAb, Plus Dostarlimab in Advanced Melanoma

Source: 2022 ASCO Annual Meeting*
Download Slideset
June 3-7, 2022; Chicago, Illinois
In the phase I AMBER trial, the anti–TIM-3 mAb cobolimab combined with dostarlimab showed a manageable safety profile in patients with advanced solid tumors and preliminary antitumor activity in patients with advanced melanoma.
Format: Microsoft PowerPoint (.ppt)
File Size: 193 KB
Released: June 20, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings